Eligard (leuprorelin acetate depot injection) - Important Safety Information from Astellas Pharma Co. Ltd. as approved by the Health Products Regulatory Authority

Notice type: 3rd Party Publications

Date: 03/12/2014

Important Safety Information communication from Astellas Pharma Co. Ltd. on risk of lack of efficacy due to incorrect reconstitution and administration process with Eligard (leuprorelin acetate depot injection).

Important Safety Information ­- Eligard (leuprorelin acetate depot injection)